Diagnostic value of circulating miR-21 for colorectal cancer: A meta-analysis

Cancer Biomarkers

Volumn 15, Issue 1, 2015, Pages 47-56

  Shan, Liuqun ^a   Ji, Qian ^a   Cheng, Gongming ^a   Xia, Jianguo ^a   Liu, Delin ^a   Wu, Changde ^a   Zhu, Benlei ^a   Ding, Yongbin ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

circulating; colorectal cancer; diagnosis; miR 21

Indexed keywords

MICRORNA 21; MICRORNAS; MIRN21 MICRORNA, HUMAN; TUMOR MARKERS, BIOLOGICAL;

ARTICLE; CANCER PATIENT; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; GOLD STANDARD; HUMAN; META ANALYSIS; OCCULT BLOOD TEST; PUBLICATION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TASK PERFORMANCE; BLOOD; COLORECTAL NEOPLASMS; GENETICS; HUMANS;

COLORECTAL NEOPLASMS; HUMANS; MICRORNAS; TUMOR MARKERS, BIOLOGICAL;

EID: 84916886637     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-140437     Document Type: Article

References (40)

1. Siegel R, Desantis C, Jemal A: Colorectal cancer statistics, 2014. CA: A Cancer Journal for Clinicians 2014; 64: 104-117.
2. Vogelaar I, van Ballegooijen M, Schrag D, Boer R, Winawer SJ, Habbema JD, Zauber AG: How much can current interventions reduce colorectal cancer mortality in the u.S. Mortality projections for scenarios of risk-factor modification, screening, and treatment. Cancer 2006; 107: 1624-1633.
3. Chen W, Liu Q, Tan SY, Jiang YH: Association between carcinoembryonic antigen, carbohydrate antigen 19-9 and body mass index in colorectal cancer patients. Molecular and Clinical Oncology 2013; 1: 879-886.
4. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC, Jr., Asco: Asco 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. Journal of clinical oncology: Official journal of the American Society of Clinical Oncology 2006; 24: 5313-5327.
5. Collins JF, Lieberman DA, Durbin TE, Weiss DG, Veterans Affairs Cooperative Study G: Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: A comparison with recommended sampling practice. Annals of Internal Medicine 2005; 142: 81-85.
6. Kim VN, Han J, Siomi MC: Biogenesis of small rnas in animals. Nature Reviews Molecular Cell Biology 2009; 10: 126-139.
7. Lewis BP, Burge CB, Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microrna targets. Cell 2005; 120: 15-20.
8. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M: Circulating micrornas as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences of the United States of America 2008; 105: 10513-10518.
9. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY: Characterization of micrornas in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell research 2008; 18: 997-1006.
10. Lu Z, Liu M, Stribinskis V, Klinge CM, Ramos KS, Colburn NH, Li Y: Microrna-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 2008; 27: 4373-4379.
11. Tao J, Lu Q,Wu D, Li P, Xu B, QingW,Wang M, Zhang Z, Zhang W: Microrna-21 modulates cell proliferation and sensitivity to doxorubicin in bladder cancer cells. Oncology Reports 2011; 25: 1721-1729.
12. Tang D, Shen Y, Wang M, Yang R, Wang Z, Sui A, Jiao W, Wang Y: Identification of plasma micrornas as novel noninvasive biomarkers for early detection of lung cancer. European journal of cancer prevention: The Official Journal of the European Cancer Prevention Organisation 2013; 22: 540-548.
13. Liu R, Chen X, Du Y, Yao W, Shen L,Wang C, Hu Z, Zhuang R, Ning G, Zhang C, Yuan Y, Li Z, Zen K, Ba Y, Zhang CY: Serum microrna expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clinical Chemistry 2012; 58: 610-618.
14. Yuan J, Chen L, Chen X, Sun W, Zhou X: Identification of serum microrna-21 as a biomarker for chemosensitivity and prognosis in human osteosarcoma. The Journal of International Medical Research 2012; 40: 2090-2097.
15. Toiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y, Kusunoki M, Boland CR, Goel A: Serum mir-21 as a diagnostic and prognostic biomarker in colorectal cancer. Journal of the National Cancer Institute 2013; 105: 849-859.
16. Xia X, Yang B, Zhai X, Liu X, Shen K,Wu Z, Cai J: Prognostic role of microrna-21 in colorectal cancer: A meta-analysis. PloS one 2013; 8: e80426.
17. Wang Y, Gao X, Wei F, Zhang X, Yu J, Zhao H, Sun Q, Yan F, Yan C, Li H, Ren X: Diagnostic and prognostic value of circulating mir-21 for cancer: A systematic review and metaanalysis. Gene 2014; 533: 389-397.
18. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J: The development of quadas: A tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Medical Research Methodology 2003; 3: 25.
19. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH: Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. Journal of Clinical Epidemiology 2005; 58: 982-990.
20. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A: Meta-disc: A software for meta-analysis of test accuracy data. BMC Medical Research Methodology 2006; 6: 31.
21. Dinnes J, Deeks J, Kirby J, Roderick P: A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy. Health Technology Assessment 2005; 9: 1-113, iii.
22. Rosenfeld RM, Shiffman RN: Clinical practice guidelines: A manual for developing evidence-based guidelines to facilitate performance measurement and quality improvement. Otolaryngology-head and neck surgery: official journal of American Academy of Otolaryngology-Head and Neck Surgery 2006; 135: S1-28.
23. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA: Micrornas in body fluids - the mix of hormones and biomarkers. Nature Reviews Clinical Oncology 2011; 8: 467-477.
24. Zen K, Zhang CY: Circulating micrornas: A novel class of biomarkers to diagnose and monitor human cancers. Medicinal Research Reviews 2012; 32: 326-348.
25. Lakomy R, Sana J, Hankeova S, Fadrus P, Kren L, Lzicarova E, Svoboda M, Dolezelova H, SmrckaM, Vyzula R,Michalek J, Hajduch M, Slaby O: Mir-195, mir-196b, mir-181c, mir-21 expression levels and o-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients. Cancer Science 2011; 102: 2186-2190.
26. Fu C, Dong W, Wang Z, Li H, Qin Q, Li B: The expression of mir-21 and mir-375 predict prognosis of esophageal cancer. Biochemical and Biophysical Research Communications 2014; 446: 1197-1203.
27. Petrovic N, Mandusic V, Stanojevic B, Lukic S, Todorovic L, Roganovic J, Dimitrijevic B: The difference in mir-21 expression levels between invasive and non-invasive breast cancers emphasizes its role in breast cancer invasion. Med Oncol 2014; 31: 867.
28. Wang P, Zhuang L, Zhang J, Fan J, Luo J, Chen H, Wang K, Liu L, Chen Z, Meng Z: The serum mir-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and mir-21 expression confers chemoresistance by targeting fasl. Molecular Oncology 2013; 7: 334-345.
29. Schee K, Boye K, Abrahamsen TW, Fodstad O, Flatmark K: Clinical relevance of microrna mir-21, mir-31, mir-92a, mir- 101, mir-106a and mir-145 in colorectal cancer. BMC Cancer 2012; 12: 505.
30. Menendez P, Padilla D, Villarejo P, Palomino T, Nieto P, Menendez JM, Rodriguez-Montes JA: Prognostic implications of serum microrna-21 in colorectal cancer. Journal of Surgical Oncology 2013; 108: 369-373.
31. Walsh JM, Terdiman JP: Colorectal cancer screening: Scientific review. JAMA : the journal of the American Medical Association 2003; 289: 1288-1296.
32. Yang X, Zeng Z, Hou Y, Yuan T, Gao C, Jia W, Yi X, Liu M: Microrna-92a as a potential biomarker in diagnosis of colorectal cancer: A systematic review and meta-analysis. PloS One 2014; 9: e88745.
33. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM: The diagnostic odds ratio: A single indicator of test performance. Journal of Clinical Epidemiology 2003; 56: 1129-1135.
34. Gallagher EJ: Clinical utility of likelihood ratios. Annals of Emergency Medicine 1998; 31: 391-397.
35. Lijmer JG, Bossuyt PM, Heisterkamp SH: Exploring sources of heterogeneity in systematic reviews of diagnostic tests. Statistics in Medicine 2002; 21: 1525-1537.
36. Ogata-Kawata H, Izumiya M, Kurioka D, Honma Y, Yamada Y, Furuta K, Gunji T, Ohta H, Okamoto H, Sonoda H, Watanabe M, Nakagama H, Yokota J, Kohno T, Tsuchiya N: Circulating exosomal micrornas as biomarkers of colon cancer. PloS One 2014; 9: e92921.
37. Liu GH, Zhou ZG, Chen R, Wang MJ, Zhou B, Li Y, Sun XF: Serum mir-21 and mir-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. Tumour biology: The journal of the International Society for Oncodevelopmental Biology and Medicine 2013; 34: 2175-2181.
38. Kanaan Z, Rai SN, Eichenberger MR, Roberts H, Keskey B, Pan J, Galandiuk S: Plasma mir-21: A potential diagnostic marker of colorectal cancer. Annals of Surgery 2012; 256: 544-551.
39. Wang B, Zhang Q: The expression and clinical significance of circulating microrna-21 in serum of five solid tumors. Journal of Cancer Research and Clinical Oncology 2012; 138: 1659-1666.
40. Ruopp MD, Perkins NJ, Whitcomb BW, Schisterman EF: Youden index and optimal cut-point estimated from observations affected by a lower limit of detection. Biometrical Journal Biometrische Zeitschrift 2008; 50: 419-430.